ReviewBiochemical Society transactions2022
Relationship between mucosa-associated gut microbiota and human diseases.
Review in Biochemical Society transactions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Bibliometric analysis of research on intestinal flora and primary biliary cholangitis published between 2004 and 2024 using VOSviewer and CiteSpace visualization.Frontiers in medicine · 2025Pooled it
- Spatial mapping of human colonic niches reveals rapid, mucus-specific microbiota disruption after bowel cleansing.Gut microbes · 2026Article
- Ecological Patterns of Gut Microbiota During Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis.Microorganisms · 2026Article
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
- Deciphering themSphere · 2026Article
- A polymer that reinforces luminal barrier function and attenuates inflammation in murine colitis.Research square · 2026Article
- Article
- Integrative host transcriptomic and mucosal microbiome profiling reveals region-specific host-microbiome associations across the human intestine.bioRxiv : the preprint server for biology · 2026Article
- Mucin Type Drives Composition and Mucin Glycan Degradation of an In Vitro Synthetic Microbial Community.Environmental microbiology · 2026Article
- The Human Gut Microbiome Activity Is Resilient and Stable for up to Six Months: A Large Stool Metatranscriptomic Study.Microorganisms · 2026Article
- Timekeepers of the gut: host circadian rhythms and microbial modulators.Life metabolism · 2026Review
- Association between bone marrow donor origin and gut microbiota composition following fecal microbiota transplantation in mice.Scientific reports · 2026Article
- Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota.Pharmaceutics · 2026Review
- Down-Regulation of Acyloxyacyl Hydrolase Expression in Alzheimer's Disease Impairs LPS Detoxification and Contributes to Brain Pro-Inflammatory Signaling.Molecules (Basel, Switzerland) · 2026Article
- Advances in Functional Foods: Using Double Emulsion Gels to Deliver CBD and Probiotics and to Modulate Human Gut Microbial Communities.Nutrients · 2026Article
- The Response of Mucosal Colonic Microbiota to Probiotic and Dietary Intervention In Vitro.Microorganisms · 2026Article
- Article
- Oral microbiota-driven immune modulation along the oral-gut axis: from local signals to systemic inflammation.NPJ biofilms and microbiomes · 2026Review
- Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn's disease.Frontiers in cellular and infection microbiology · 2026Article
- Distinct mucosa-associated microbiota signatures and dysbiosis in Peutz-Jeghers syndrome polyps versus paired normal mucosa.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The mucus layer covering the gastrointestinal (GI) tract plays a critical role in maintaining gut homeostasis. In the colon, the inner mucus layer ensures commensal microbes are kept at a safe distance from the epithelium while mucin glycans in the outer mucus layer provide microbes with nutrients and binding sites. Microbes residing in the mucus form part of the so-called 'mucosa-associated microbiota' (MAM), a microbial community which, due to its close proximity to the epithelium, has a profound impact on immune and metabolic health by directly impacting gut barrier function and the immune system. Alterations in GI microbial communities have been linked to human diseases. Although most of this knowledge is based on analysis of the faecal microbiota, a growing number of studies show that the MAM signature differs from faecal or luminal microbiota and has the potential to be used to distinguish between diseased and healthy status in well-studied conditions such as IBD, IBS and CRC. However, our knowledge about spatial microbial alterations in pathogenesis remains severely hampered by issues surrounding access to microbial communities in the human gut. In this review, we provide state-of-the-art information on how to access MAM in humans, the composition of MAM, and how changes in MAM relate to changes in human health and disease. A better understanding of interactions occurring at the mucosal surface is essential to advance our understanding of diseases affecting the GI tract and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.